Navigation Links
Myeloperoxidase Research Expands
Date:12/8/2008

ST. LOUIS, Dec. 8 /PRNewswire/ -- www.leebio.com, Lee Biosolutions, Inc continues to increase its capacity for stable Human Myeloperoxidase enzyme for clinical diagnostic, pharmaceutical manufacturers and clinical researchers worldwide due to high demand.

Current research on this important Myeloperoxidase protein has expanded from acute lung injury, acute inflammation to multiple sclerosis, diabetes, stroke and gastric cancer prediction. Great deal of worldwide research continues with this important enzyme that Lee Biosolutions produces.

Three Myeloperoxidase isoforms have been purified and identified through ion exchange chromatography by Lee Biosolutions. Human Myeoloperoxidase Isoform A, Myeloperoxidase isoform B and Myeloperoxidase isoform C. MPO C is a popular enzyme among the community of protein structural researchers, including X-ray crystallographers. Lee Biosolutions whole Myeloperoxidase 426- 10 is popular among major Clinical Diagnostic manufacturers.

According to company President Burton Lee, Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continue to be developed in order to meet the demands of our clients.

"We understand the critical role our products play in the clinical research process," Lee said. "By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of Myeloperoxidase products."

    Press Release Contact Information:
    Burton Lee
    President
    Lee Biosolutions, Inc
    314-968-1091
    burton@leebio.com

This release was issued through WebWire(R). For more information visit http://www.webwire.com.


'/>"/>
SOURCE Lee Biosolutions, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
2. Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes
3. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):